Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: STEPHEN SHERWIN - CELL GENESYS INC (CEGE).


(PAL231) STEPHEN SHERWIN - CELL GENESYS GENESYS Generation System
GENESYS Generic Systems Simulator
 INC (CEGE). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: CEGE. Complete text approximately 3000 words. Document # PAL231.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: STEPHEN SHERWIN - CELL GENESYS INC (CEGE).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:89
Previous Article:CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
Next Article:CEO INTERVIEW: EDWARD LANPHIER II - SANGAMO BIOSCIENCES INC (SGMO).
Topics:



Related Articles
Cell Genesys receives patent for adeno-associated virus gene therapy
Cell Genesys to receive broad European patent for gene activation technology.
Cell Genesys receives $2 million patent milestone payment from Hoechst Marion Roussel under gene activation license agreement.
Cell Genesys issued patent for adeno-associated viral gene therapy.
Cell Genesys exclusively licenses technology for liver-directed Aav gene therapy from University of Washington.
Crucell signs licensing deal with Cell Genesys for Per.C6 packaging cell technology.
ANALYST INTERVIEW: GENOMICS & GENE-BASED THERAPEUTICS: ALBERT RAUCH - LADENBURG THALMANN & CO.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles